Fig. 3.

Differences in mFARS values (Omaveloxolone-placebo) (mean ± SD) in part 1 (week 12), part 2 (week 48), and part 3 (EW 72) in patients without pes cavus according to each study. Baseline values in part 1 include the data of patients with pes cavus. The baseline values are the initial values obtained at the time of patient recruitment. The baseline value in part 3 is the same as that in part 2